计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| B408280-1ml |
1ml |
现货 ![]() |
|
| 英文别名 | BGB324 | 1H-1,2,4-Triazole-3,5-diamine, 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-[(7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl]- |
|---|---|
| 规格或纯度 | Moligand™, 10mM in DMSO |
| 英文名称 | Bemcentinib (R428) |
| 生化机理 | Bemcentinib(R428,BGB324)是一种 Axl 抑制剂,IC50 为 14 nM,对 Axl 的选择性是 Abl 的 100 倍以上。对 Axl 的选择性也高于 Mer 和 Tyro3(选择性高 50-100 倍)以及 InsR、EGFR、HER2 和 PDGFRβ(选择性高 100 倍)。 |
| 储存温度 | -80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 酪氨酸蛋白激酶受体 UFO 抑制剂 |
| 产品介绍 |
Bemcentinib (R428, BGB324)是一种Axl抑制剂,IC50为14 nM,作用于Axl比作用于Abl选择性高100倍以上。作用于Axl选择性也比作用于Mer和Tyro3(高50到100倍)及InsR, EGFR, HER2,和PDGFRβ(高100倍以上)高。 R428是一种选择性的Axl抑制剂,IC50值为14 nM。与Abl、Mer、Tyro3、InsR、EGFR、HER2和PDGFR相比,R428对Axl具有超过50倍的灵敏度。 Axl受体酪氨酸激酶通过结合维生素K依赖性蛋白growth arrest-specific 6 (Gas6)将细胞外基质信号传导到胞浆内。Axl参与多个细胞内进程,包括细胞生长、迁移、聚集和抗炎活性。 R428在低纳摩尔浓度下就可以阻断Axl的催化活性,同时抑制Axl依赖的活性,包括Akt磷酸化、细胞侵袭、促炎因子的产生。R428可以减少粒细胞巨噬细胞集落刺激因子和上皮-间质转化转录因子Snail的表达。R428还可以抑制血管生成,减少转移性肿瘤负荷,在动物异种移植模型中提高生存率。此外,R428与cisplatin协同作用可以提高肝脏微转移的抑制效率。 Information Bemcentinib (R428) Bemcentinib (R428, BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100 R428 blocks the catalytic and procancerous activities of Axl. R428 inhibits Axl with low nanomolar activity and blocks Axl-dependent events, including Akt phosphorylation, breast cancer cell invasion, and proinflammatory cytokine production. In a recent study, the Axl inhibitor R428 shows a mean IC50 dose of ∼ 2.0μM for the primary CLL B cells after 24 hours of treatment and normal B-, T-, and natural killer (NK) cells show no significant amount of cell death at this dose of R428 (2.5 μM) under similar experimental conditions. In vivo Pharmacologic investigations reveal favorable exposure after oral administration such that R428-treated tumors display a dose-dependent reduction in expression of the cytokine granulocyte macrophage colony-stimulating factor and the epithelial-mesenchymal transition transcriptional regulator Snail. In support of an earlier study, R428 inhibits angiogenesis in corneal micropocket and tumor models. R428 administration reduces metastatic burden and extends survival in MDA-MB-231 intracardiac and 4T1 orthotopic (median survival, >80 days compared with 52 days; P < 0.05) mouse models of breast cancer metastasis. cell lines: Concentrations: Incubation Time: Powder Purity:≥98% |
| 分子类型 | 小分子 |
|---|---|
| Isomeric SMILES | C1CCN(C1)[C@H]2CCC3=C(CC2)C=C(C=C3)NC4=NN(C(=N4)N)C5=NN=C6C(=C5)CCCC7=CC=CC=C76 |
| PubChem CID | 46215462 |
| 分子量 | 506.64 |